Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced its bitXbio ...

Evofem Biosciences (NASDAQ:EVFM) just reported results for the second quarter of 2024. The company did not report any EPS for the quarter. The company reported revenue of $4.16 million.

Evofem CEO Saundra Pelletier, whose base salary in 2021 was $812,083, has agreed to a 40% reduction in her salary. The other remaining members of the executive team will receive 20% less than the ...

Evofem Biosciences, the buzzy but controversial women’s health startup that spent the past year trying to stay afloat, has finally found a buyer.. The San Diego company, which makes the ...

Evofem Biosciences now trades at around 80 cents a share, after hitting a high of $1.57 in early July. (The stock was below 40 cents before the Supreme Court ruling.) ...

--Evofem Biosciences, Inc. today announced that the United States Patent and Trademark Office issued to the Company a Notice of Allowance for patent application 17/ 028,838, ...

Evofem's commercial team relaunched SOLOSEC in November 2024, and promotes the product alongside PHEXXI to OB/GYNs in the U.S. The Company is entering global markets through strategic ...

Evofem used a portion of this funding to pay in full its obligations to the U.S. Food and Drug Administration. As of December 31, 2024, the Company had $0.7 million of restricted cash, ...

Evofem also plans to potentially expand its women’s health portfolio with tests developed by Aditxt's subsidiary Pearsanta, including a Mitomic ovarian test for early detection of ovarian cancer.

SAN DIEGO, June 11, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) today announced that a study of SOLOSEC® (secnidazole) 2 g oral granules for recurrent ...